EAACI Congress 2025
BackFT16 - Immunodeficiencies and autoimmunity
Sunday 15 Jun, 14:00 PM -
15:30 PM Glasgow, United Kingdom
Dochart 1
Flash Talks
14:00
Safety and Efficacy of Oral Deucrictibant for Treatment of Upper Airway and Laryngeal Hereditary Angioedema Attacks: Results from the RAPIDe-2 Extension Study
14:07
Long-Term Prophylactic Treatment With Oral Deucrictibant Improves Disease Control and Health-Related Quality of Life in Participants With Hereditary Angioedema in the CHAPTER-1 Open-Label Extension Study
14:14
Assessment of the Effectiveness and Tolerability of Berotralstat for Long-term Prophylaxis in Hereditary Angioedema: Findings from the Berolife Study
14:21
Substantial and Sustained Reductions in Physician-Reported Attack Rates With Lanadelumab in Patients With Hereditary Angioedema: Final Data From the ENABLE Study
14:28
CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks
14:35
Berotralstat Use Reduced Number of HAE Attacks Requiring Treatment or Professional Care in Pediatric Patients: Interim Results from APeX-P
14:42
Latent Tuberculosis in Inborn Errors of Immunity: Role of Tuberculin Skin Testing
14:49
Evaluation of Sleep and Quality of Life in Patients Receiving Immunoglobulin Replacement Therapy for Inborn Errors of Immunity
14:56
Cutaneous Manifestations in Inborn Errors of Immunity: A Retrospective Analysis of Prevalence, Phenotypes, and Treatment Outcomes
15:03
Kabuki syndrome: unmasking the clinical and immunological profile in pediatric patients
